The Global Immunotherapy-based Pet Cancer Therapeutics Market was estimated to be worth USD 6.12 billion in 2023 and is projected to reach a value of USD 12.95 billion by 2030, growing at a CAGR of 11.3% during the forecast period 2024-2030.
Specialized medical care known as "pet cancer therapy" is used to diagnose, treat, and manage cancer in animals such as cats and dogs. It includes similar treatments to those given to cancer patients in humans, such as immunotherapy, chemotherapy, radiation therapy, targeted therapies, and palliative care. These therapies are offered by veterinary oncologists to aid animals suffering from various cancers and enhance their quality of life. With the advancement of veterinary medicine, pet owners can now provide their beloved pets with comprehensive and compassionate treatment for cancer, thanks to the increased availability and effectiveness of these therapies. Boehringer Ingelheim International GmbH's NexGard PLUS, a new chewable tablet that guards against both internal and external parasites, has received FDA approval. Its active components, which include pyrantel, moxidectin, and afoxolaner, combine to offer a potent defense against common parasite threats. Bexacat (bexagliflozin tablets) received FDA clearance, marking a significant milestone for Elanco Animal Health Incorporated. This novel oral therapy is the first of its kind for feline diabetes and presents a fresh method of treating the illness without injecting insulin. Bexacat tablets fill a gap in veterinary medicine and are simple to use. Leading biotechnology business ELIAS Animal Health LLC, which specializes in treating cancer in pets, has made a noteworthy development in oncolytic virotherapy. Utilizing a modified strain of the vaccinia virus, their ground-breaking Oncolytic Vaccinia Virus Treatment—which Genelux Corporation has now licensed—targets and eliminates cancer cells in companion animals. Because the virus can selectively infect and kill cancer cells while sparing healthy tissue, this therapy offers a novel approach to treating a variety of pet cancers.
Key Market Insights:
Monoclonal antibody therapies account for approximately 35% of the immunotherapy-based pet care therapeutics market share, driven by their targeted approach and effectiveness in treating various conditions, particularly in oncology.
The canine segment constitutes around 60% of the market demand for immunotherapy-based pet care therapeutics, reflecting the larger population of dogs as pets and the higher incidence of certain diseases amenable to immunotherapy in canines.
In terms of application, cancer immunotherapy represents about 45% of the market share, as cancer remains one of the leading causes of death in companion animals and immunotherapy offers promising treatment options.
The adoption of personalized immunotherapy treatments for pets, tailored to an individual animal's specific condition and genetic profile, is growing at a rate of approximately 18% annually, driven by advancements in veterinary medicine and the increasing willingness of pet owners to invest in cutting-edge treatments for their animals.
Global Immunotherapy-based Pet Cancer Therapeutics Market Drivers:
Expanding pet ownership and the human-animal bond can support industry growth:
The growing number of pet owners and their growing emotional attachment to their animals has had a significant impact on the market for cancer therapies for animals. Many people feel deeply responsible for the health and well-being of their pets because they view them as beloved family members. This attachment prompts pet owners to spend more money on cutting-edge cancer therapies in an effort to heal ailments and improve the quality of life for their animals. Pet owners are becoming more willing to spend money on innovative cancer therapies that can better treat their pets' conditions, reduce their pain, and lengthen their lives. This demand highlights a growing need for effective treatments that address these issues and reflects a desire to give their cherished animals the best care possible.
Current technological advancements will propel market expansion:
Ongoing research and studies have played a major role in the recent advances in animal oncology and therapy. Researchers have devoted their efforts to developing novel anticancer drugs, increasing their potency, and reducing any potential harm to pets' health. This dedication is essential as groups like the Petco Foundation, the Animal Cancer Foundation, the PetCure Oncology Veterinary Cancer Society, and others work together to create targeted cancer treatments with low side effects. Growing funding for oncology research in animals is propelling the creation of novel cancer therapies that put patient safety and effectiveness first. This funding expedites advancement in both fields by supporting research initiatives meant to identify commonalities between canine and human cancers. The ultimate objective is to progress cancer treatment options, enhancing quality of life and improving outcomes through novel therapies, for both humans and pets.
Immunotherapy-based Pet Cancer Therapeutics Market Challenges and Restraints:
One major obstacle to the global market for cancer drugs is the cost of pet cancer therapies. Pet owners may face significant financial hardships due to the costs of diagnostics, procedures, radiation therapy, and prescription drugs. Many pet owners are unable to afford advanced cancer treatments due to their high costs, which forces them to make difficult decisions about the level of care they can provide for their animals. Pricing is still a major problem for pet cancer medications, even in the face of growing demand and awareness. Restricting access to these treatments modifies market dynamics and influences the availability and uptake of advanced therapies in general. In order to guarantee that pets receive the best care possible without financial limitations limiting treatment options, it is still imperative that these cost challenges be addressed.
Immunotherapy-based Pet Cancer Therapeutics Market Opportunities:
The way that money is spent on veterinary care has changed significantly because people now view their pets as loved family members rather than merely companions. Due to this evolution, pet owners are now much more willing to spend money on giving their dogs long, healthy lives. The cost of treating cancer in pets has increased as a result of increased awareness of the available cancer therapy options. More and more pet owners are prepared to spend money on cutting-edge cancer treatments in an effort to enhance the general health and well-being of their animals. This pattern demonstrates a great desire to give their animals the best care possible. The general rise in veterinary healthcare expenditures is another factor driving the market for cancer treatments for pets. Opportunities for research, creativity, and the creation of cutting-edge cancer treatment options for pets are made possible by this financial support. As a result, new approaches to pet cancer therapy are constantly emerging, improving the prognosis and quality of life for animals with the disease.
IMMUNOTHERAPY-BASED PET CANCER THERAPEUTICS MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
11.3% |
|
Segments Covered |
By Route of Administration, animal, Application, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
AB Science, Boehringer Ingelheim International GmbH, ELIAS Animal Health LLC, Karyopharm Therapeutics,Pfizer Inc., Regeneus Ltd., Rhizen Pharmaceuticals AG, Torigen Pharmaceuticals Inc., VetDC Inc., Virbac, Zoetis Inc. |
Oral
Injection
With a 47% market share in 2022, oral administration overtook other categories as the most popular category for immunotherapy-based pet cancer treatments. This dominance is ascribed to the accessibility of different oral immunotherapy options, including liquids, pills, and capsules, which provide easy administration at a reasonable cost. Anticipating future developments, the injectable mode of administration is anticipated to grow at the quickest rate, with a compound annual growth rate (CAGR) of 10.2% over the estimated period. This projected growth is due to a number of factors, including the perception that injectable therapies are more effective than oral ones, acting more quickly and carrying a lower risk of side effects. The range and effectiveness of injectable immunotherapy options for treating pet cancer are also being increased by developments in injectable technologies, such as intratumoral and subcutaneous injection equipment.
Dogs
Cats
With 52% of cases worldwide, dogs account for a larger share of the pet cancer therapy market than cats or other animals. Dog owners are generally more willing to seek out and pay for cancer treatments for their cherished pets, and dogs have a higher incidence of cancer than cats or other pets. These factors contribute to the dominance of dogs over other pet species. The growth of the industry has been further supported by the fact that significant research and development efforts in canine cancer treatments have been sparked by the genetic similarities between humans and dogs. On the other hand, with a projected growth rate of 39%, cats are predicted to have the fastest growth rate in the pet cancer therapy market. This increase is caused by a number of factors, including the fact that cats typically live longer than many other pets, which makes them more vulnerable to age-related diseases like cancer. Additionally, the number of cats worldwide is increasing steadily, which expands the pool of possible patients. The ability to identify and treat cancer in cats has improved due to advancements in feline healthcare and diagnostics, which has increased the demand for specialized therapies catered to the unique needs of felines. In summary, cats are positioned for rapid growth driven by their longer lifespans, increasing population, and advancements in feline healthcare, while dogs currently dominate the market for pet cancer therapies due to higher incidence rates and owners' willingness to invest in treatments. The continuous efforts to improve pet cancer treatments through research and development are beneficial to both segments.
Lymphoma
Mast Cell Cancer
Melanoma
Mammary
Squamous Cell Cancer
Others
Due to a number of factors, lymphoma has the largest share (38%) of pet cancer treatments worldwide. Both dogs and cats can develop lymphoma, a cancer that is frequently treated effectively with a variety of veterinary oncology treatment options. Treatment developments, such as customized chemotherapy regimens, have greatly enhanced the prognosis of pets with lymphoma. Its dominant position in the market is a result of a combination of high incidence rates and generally positive treatment outcomes. Conversely, at 24%, melanoma is growing at the fastest rate in the market. There are other reasons for this increase as well. Melanoma is a kind of skin cancer that can affect both dogs and cats, and its occurrence has been rising recently. Currently, pet owners are keeping a closer eye on the condition of their pets' skin, which allows for early detection and treatment. Furthermore, developments in veterinary oncology have led to more precise and effective treatments created especially for the management of melanoma in animals. The melanoma category in the pet cancer therapeutics market is growing due to consumer demand for customized treatments designed for this particular cancer type.
North America
Europe
Asia-Pacific
South America
Middle East and Africa
With a commanding 48% market share, the North American region is set to lead the pet cancer therapeutics sector. The prevalence of pet cancers, growing per capita veterinary care spending, rising pet adoption rates, a strong healthcare system, and the existence of significant market players are some of the factors contributing to this dominance. With almost 90 million dog owners in the US alone, the market for pet cancer treatments has significant potential in this area. The need for efficient healthcare solutions is growing along with awareness of pet health issues. On the other hand, with an anticipated growth rate of 33%, the Asia-Pacific region is witnessing the fastest growth in the pet cancer treatment market. Pet ownership is expanding quickly in nations like China and India thanks to rising middle class and disposable income levels. Alongside this shift in culture toward pet ownership, there is a growing demand for cutting-edge treatment options due to increased awareness of pet health issues, such as cancer. The availability of specialized veterinary care centered on cancer therapies and growing public awareness are driving the rapid evolution of the pet healthcare sector in the region.
COVID-19 Impact on the Global Immunotherapy-based Pet Cancer Therapeutics Market:
Due to alterations in the veterinary healthcare system, the pet cancer treatment market experienced considerable difficulties and slower growth during the COVID-19 pandemic. According to the 2020 report from the Global Animal Health Association, a lot of pet owners reported that their animals had delays or missed veterinary appointments, which is indicative of larger problems with access to veterinary care. The availability of regular and specialized care for pets, including cancer treatments, was impacted by these disruptions. To protect their pets' health during the pandemic, pet owners resorted more and more to pet medications in response to these difficulties. This change in consumer behavior raised the demand for pet health medications intended to prevent and treat chronic illnesses, such as cancer. Despite these challenges, the coordinated efforts of animal welfare organizations—which supplied crucial services and support during the pandemic—benefited the animal healthcare system. During the COVID-19 disruptions, these organizations were instrumental in advancing therapies and maintaining continuity in pet care.
Latest Trend/Development:
Trends and advancements in immunotherapy-based pet care therapeutics are happening quickly. In order to make pet treatments safer and more effective, researchers are always working to improve them. Because oral immunotherapy is simple for pet owners to administer, it continues to be popular for use in pill and liquid form. Because they act quickly and have fewer side effects, injectables like intratumoral and subcutaneous injections are becoming more and more popular. Utilizing genetic data and health profiles, personalized treatments catered to the specific requirements of each pet are becoming increasingly popular. The development of novel, targeted treatments is also aided by technologies such as AI and genomics. The safety and efficacy of these treatments are guaranteed by regulatory approvals and standards.
Key Players:
AB Science
Boehringer Ingelheim International GmbH
Elanco Animal Health Incorporated
ELIAS Animal Health LLC
Karyopharm Therapeutics
Pfizer Inc.
Regeneus Ltd.
Rhizen Pharmaceuticals AG
Torigen Pharmaceuticals Inc.
VetDC Inc.
Virbac
Zoetis Inc.
Market News:
To help save the lives of animals in Fort Wayne, Petco Love, a nationwide nonprofit organization, gave $35,000 to Fort Wayne Animal Care and Control in July 2022.
June 2022 saw Petco Love uphold its long-standing commitment to the Cornell University College of Veterinary Medicine by contributing $75,000 to help defray the cost of dogs' and cats' cancer treatments. These contributions demonstrate Petco Love's dedication to promoting veterinary care and animal welfare.
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
The Global Immunotherapy-based Pet Cancer Therapeutics Market was estimated to be worth USD 6.12 billion in 2023 and is projected to reach a value of USD 12.95 billion by 2030, growing at a CAGR of 11.3% during the forecast period 2024-2030.
Growing the human-animal relationship and pet ownership can help the industry grow and Modern technical developments that will push the market growth are the factors driving the Global Immunotherapy-based Pet Cancer Therapeutics Market.
The market's expansion may be hampered by high treatment costs.
Melanoma application type is the fastest growing in the Global Immunotherapy-based Pet Cancer Therapeutics Market.
Asia-Pacific region is the fastest growing in the Global Immunotherapy-based Pet Cancer Therapeutics Market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
